Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

25,442 signal articles · 193 in last 24h · 121,618 total before filter · latest 1h ago
193last 24h
1277last 7d
217● bullish (7d)
152● bearish (7d)
205publishers
AllMacro212Earnings443M&A100Regulatory26Product9Analyst13
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
How Investors Are Reacting To Deckers (DECK) Upgraded 2027 Guidance And Teva Product Expansion
Simply Wall St.23d agobullish
How Investors Are Reacting To Deckers (DECK) Upgraded 2027 Guidance And Teva Product Expansion

Earlier this month, Deckers Outdoor reported first-quarter 2026 sales of US$1,019.53 million with net income of US$129.97 million, and raised its full-year fiscal 2027 guidance to net sales of US$5.86–5.91 billion, operating margin slightly above 21.5%, and diluted EPS of US$7.35–7.50, assuming share repurchases equal to roughly 80% of projected free cash flow. Alongside the guidance upgrade, Deckers’ Teva division rolled out an extensive Fall 2026 performance and lifestyle lineup, including...

Flex Q1 Earnings Call Highlights
MarketBeat23d agoneutral
Flex Q1 Earnings Call Highlights

Flex (NASDAQ:FLEX) reported first-quarter fiscal 2027 results that included 21% revenue growth, expanding margins and record adjusted earnings per share, while management said the company remains on track to separate its Cloud and Power Infrastructure business into an independent company in the firs

Biogen Q2 Earnings Call Highlights
MarketBeat23d agoneutral
Biogen Q2 Earnings Call Highlights

Biogen (NASDAQ:BIIB) reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year earlier, as growth products and the recently completed acquisition of Apellis contributed to results. Core pharmaceutical revenue rose 4% year over year to $1.8 billion, while the company’s growth port

Bloom Energy Soars 11% on Record $1.07B Q2 Revenue, Raised 2026 Guidance
24/7 Wall St.23d agoneutral
Bloom Energy Soars 11% on Record $1.07B Q2 Revenue, Raised 2026 Guidance

Shares of Bloom Energy (NYSE:BE) advanced 11% to $185.85 in early Wednesday trading after the fuel cell maker delivered a blowout Q2 2026 earnings beat and raised full-year guidance. The move flipped Tuesday’s pre-earnings selloff, when Bloom Energy shares fell 13% amid short-seller pressure from Hunterbrook. However, BE stock soon retreated to $173.29, up 4% ... Bloom Energy Soars 11% on Record $1.07B Q2 Revenue, Raised 2026 Guidance

Teradyne Stock Jumps as Earnings Guidance Does the Seemingly Impossible—Impresses Wall Street
Barrons.com23d agobullish
Teradyne Stock Jumps as Earnings Guidance Does the Seemingly Impossible—Impresses Wall Street

It takes a lot for artificial-intelligence trade-related companies to impress Wall Street with earnings or guidance these days, but Teradyne has done just that. Shares of the semiconductor test equipment manufacturer rose 9% to $338.43 on Wednesday after the company late Tuesday reported better-than-expected second-quarter earnings and solid quarterly guidance. Teradyne posted adjusted earnings of $2.47 a share in the second quarter, up from 57 cents a year ago and well above Wall Street’s expectation of $2.09.